Vironova has filed a US provisional patent for analyzing viral vector content using cryoTEM

Vironova has now filed a patent for quantitative analysis of viral vector content using cryoTEM, a method that has already triggered plenty of interest amongst our customers.

In the pharmaceutical industry, viruses and virus-like particles are extensively used as carriers for gene delivery, so called viral vectors. Assessment of carrier particle content is of prime importance as it is directly linked to the efficacy of the treatment.

Negative stain TEM (nsTEM) is a standard approach for assessing this. Due to variations in staining and preparation the results are unreliable, whereas analysis using cryoTEM yields very consistent and reliable results. Vironova has now filed the patent for the quantitative analysis of viral vector content using cryoTEM.

Sample description (optional)

Analysis objective (optional)